Contrasting Oncology Institute (NASDAQ:TOI) and NewGenIvf Group (NASDAQ:NIVF)

Oncology Institute (NASDAQ:TOI) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Volatility & Risk

Oncology Institute has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. Comparatively, NewGenIvf Group has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500.

Institutional & Insider Ownership

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are owned by institutional investors. 8.5% of Oncology Institute shares are owned by insiders. Comparatively, 31.8% of NewGenIvf Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Oncology Institute and NewGenIvf Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-14.26%	-1,527.21%	-34.25%
NewGenIvf Group	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Oncology Institute and NewGenIvf Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1	0	2	1	2.75
NewGenIvf Group	1	0	0	0	1.00

Oncology Institute currently has a consensus price target of $7.00, indicating a potential upside of 104.08%. Given Oncology Institute’s stronger consensus rating and higher possible upside, research analysts plainly believe Oncology Institute is more favorable than NewGenIvf Group.

Valuation & Earnings

This table compares Oncology Institute and NewGenIvf Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$393.41 million	0.82	-$64.66 million	($0.68)	-5.04
NewGenIvf Group	$4.77 million	0.27	-$520,000.00	N/A	N/A

NewGenIvf Group has lower revenue, but higher earnings than Oncology Institute.

Summary

Oncology Institute beats NewGenIvf Group on 7 of the 13 factors compared between the two stocks.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

About NewGenIvf Group

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.